PYXIS ONCOLOGY
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.
PYXIS ONCOLOGY
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2019-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.pyxisoncology.com
Total Employee:
51+
Status:
Active
Total Funding:
174 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Global Site Tag Sitelinks Search Box
Current Advisors List
Board_observer
2019-07-01
Current Employees Featured
Jay Feingold Chief Medical Officer @ Pyxis Oncology
Chief Medical Officer
2021-09-01
David Steinberg CEO, Co-founder, & Director @ Pyxis Oncology
CEO, Co-founder, & Director
Martina Molsbergen Interim Chief Business Officer @ Pyxis Oncology
Interim Chief Business Officer
2021-10-01
Lara S. Sullivan Chief Executive Officer @ Pyxis Oncology
Chief Executive Officer
2019-12-01
Jay M. Feingold Chief Medical Officer @ Pyxis Oncology
Chief Medical Officer
2021-01-01
Founder
Stock Details
Investors List
Ridgeback Capital
Ridgeback Capital investment in Series B - Pyxis Oncology
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Pyxis Oncology
Leaps by Bayer
Leaps by Bayer investment in Series B - Pyxis Oncology
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Pyxis Oncology
RA Capital Management
RA Capital Management investment in Series B - Pyxis Oncology
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Pyxis Oncology
Logos Capital
Logos Capital investment in Series B - Pyxis Oncology
RTW Investments LLC
RTW Investments LLC investment in Series B - Pyxis Oncology
Tekla Capital Management
Tekla Capital Management investment in Series B - Pyxis Oncology
BVF Partners
BVF Partners investment in Series B - Pyxis Oncology
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-09 | Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business OfficerIndustry veteran brings expertise in corporate strategy and business development to Pyxis team |
Official Site Inspections
http://www.pyxisoncology.com Semrush global rank: 3.63 M Semrush visits lastest month: 3.92 K
- Host name: pyxis.wpmudev.host
- IP address: 207.246.95.246
- Location: Piscataway United States
- Latitude: 40.5511
- Longitude: -74.4606
- Metro Code: 501
- Timezone: America/New_York
- Postal: 08854
More informations about "Pyxis Oncology"
Pyxis Oncology | About Us
Pyxis Oncology is devoted to transforming the lives of patients with cancer by advancing our innovative and differentiated portfolio of clinical assets that specifically target tumor cells and …See details»
Pyxis Oncology - Crunchbase Company Profile & Funding
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.See details»
Pyxis Oncology Company Profile | Management and Employees …
Find contact information for Pyxis Oncology. Learn about their Pharmaceuticals, Manufacturing market share, competitors, and Pyxis Oncology's email format.See details»
Pyxis Oncology - LinkedIn
Pyxis Oncology | 6,293 followers on LinkedIn. Charting a course to therapeutics for difficult-to-treat cancer. | Pyxis Oncology is transforming the lives of patients with cancer by advancing our ...See details»
Contact us - Pyxis Oncology
Are you interested in learning more about Pyxis Oncology? We are always available to answer any questions you may have, and encourage you to contact us. Please complete the form …See details»
News release - Pyxis Oncology
Mar 31, 2023 Pyxis Oncology’s antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors …See details»
Pyxis Oncology
Feb 25, 2025 Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates …See details»
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 …
MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extra-cellular matrix (ECM) density, inhibiting tumor angiogenesis …See details»
Pyxis Oncology - VentureRadar
"Pyxis Oncology is an immuno-oncology company focused on developing novel therapies to help patients defeat difficult to treat cancers. Built on the ground-breaking research of Dr. Thomas …See details»
Pyxis Oncology, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care. To …See details»
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Pyxis Oncology’s antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current …See details»
Pyxis Oncology | Our Approach
Our ADC generation platform, FACT, developed by Pfizer, equips Pyxis Oncology to potentially develop next-generation ADCs with improved plasma stability, better potency and improved …See details»
Pyxis Oncology Announces Presentations at Upcoming Investor …
Since its launch in 2019, Pyxis Oncology has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical …See details»
Pyxis Oncology, Inc. (Pyxis Oncology, Inc.) - 药物管线_专利_临床试 …
Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant or refractory to current standards of …See details»
Pyxis Oncology to Present New Preclinical Data Supporting
1 day ago To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn. Forward-Looking StatementsSee details»
Pyxis Oncology Initiates New PYX-201 Combination Trial and …
Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant or refractory to current standards of …See details»
Pyxis Oncology Granted FDA Fast Track Designation for
Feb 26, 2025 Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer Designation applies to the …See details»
Pyxis Oncology Founded by Longwood Fund with Financing Led …
Jul 17, 2019 Building on New Insights in Tumor Biology Discovered by Award-winning Cancer Researcher Thomas Gajewski, MD, PhDUSD 22 Million Series A to Fund Pipeline of ...See details»
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 ...
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment …See details»
News release - ir.pyxisoncology.com
MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extra-cellular matrix density, inhibiting tumor angiogenesis and …See details»